| VIS ID | Virus | Ensembl ID | Gene Type | Target Gene | Oncogene | Tumor Suppressor Gene | NCBI ID | Uniprot ID |
|---|---|---|---|---|---|---|---|---|
| TVIS20031946 | HPV | ENSG00000164742.16 | protein_coding | ADCY1 | No | No | 107 | C9J1J0 Q08828 |
| TVIS20062093 | HPV | ENSG00000164742.16 | protein_coding | ADCY1 | No | No | 107 | C9J1J0 Q08828 |
| TVIS20041474 | HPV | ENSG00000164742.16 | protein_coding | ADCY1 | No | No | 107 | C9J1J0 Q08828 |
| TVIS20061695 | HPV | ENSG00000164742.16 | protein_coding | ADCY1 | No | No | 107 | C9J1J0 Q08828 |
| TVIS44025912 | HTLV-1 | ENSG00000164742.16 | protein_coding | ADCY1 | No | No | 107 | C9J1J0 Q08828 |
| TVIS44049080 | HTLV-1 | ENSG00000164742.16 | protein_coding | ADCY1 | No | No | 107 | C9J1J0 Q08828 |
| TVIS44036785 | HTLV-1 | ENSG00000164742.16 | protein_coding | ADCY1 | No | No | 107 | C9J1J0 Q08828 |
Target Gene Table
▼
TCGA Plot Options
▼
Drug Information
▼
| Gene | ADCY1 |
|---|---|
| DrugBank ID | DB00131 |
| Drug Name | Adenosine phosphate |
| Target ID | BE0000269 |
| UniProt ID | Q08828 |
| Regulation Type | product of |
| PubMed IDs | 16895552; 17229090; 11752352 |
| Citations | Yang ZF, Sun Y, Li CZ, Wang HW, Wang XJ, Zheng YQ, Liu K, Liu YM: Reduced sinoatrial cAMP content plays a role in postnatal heart rate slowing in the rabbit. Clin Exp Pharmacol Physiol. 2006 Aug;33(8):757-62.@@Nicol X, Bennis M, Ishikawa Y, Chan GC, Reperant J, Storm DR, Gaspar P: Role of the calcium modulated cyclases in the development of the retinal projections. Eur J Neurosci. 2006 Dec;24(12):3401-14.@@Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. |
| Groups | Approved; Investigational; Nutraceutical; Withdrawn |
| Direct Classification | Purine ribonucleoside monophosphates |
| SMILES | NC1=C2N=CN([C@@H]3O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]3O)C2=NC=N1 |
| Pathways | Leigh Syndrome; Histidinemia; Guanidinoacetate Methyltransferase Deficiency (GAMT Deficiency); Fatty Acid Metabolism; Gentamicin Action Pathway; Pyruvate Dehydrogenase Complex Deficiency; Purine Nucleoside Phosphorylase Deficiency; Hyperprolinemia Type II; Glutamate Metabolism; Clarithromycin Action Pathway; Argininosuccinic Aciduria; Pyruvate Decarboxylase E1 Component Deficiency (PDHE1 Deficiency); Hyperinsulinism-Hyperammonemia Syndrome; Butyrate Metabolism; Pyruvate Metabolism; Pentose Phosphate Pathway; Propanoate Metabolism; Glycine and Serine Metabolism; Selenoamino Acid Metabolism; Thiamine Metabolism; Oxytetracycline Action Pathway; Tetracycline Action Pathway; Carbamoyl Phosphate Synthetase Deficiency; Hyperprolinemia Type I; Histidine Metabolism; Cystathionine beta-Synthase Deficiency; Arginine and Proline Metabolism; Roxithromycin Action Pathway; Purine Metabolism; Ammonia Recycling |
| PharmGKB | PA164744376 |
| ChEMBL | CHEMBL752 |
